EML4‐ALK‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review
ABSTRACT We report a case showing that lorlatinib is effective in treating EML4‐ALK‐positive low‐grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ova...
Saved in:
Main Authors: | Qiongqian Li, Tongze Cai, Xiaoming Zheng, Shunrong Zhang, Chanjuan Li, Huang Tang, Zhiyong Yu, Jianlong Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.70043 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer
by: Zihua Zou, et al.
Published: (2025-01-01) -
Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
by: Jialin Qian, et al.
Published: (2025-03-01) -
Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01) -
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01) -
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)